Immunovant, Inc. (NASDAQ:IMVT) Shares Purchased by Two Seas Capital LP

Two Seas Capital LP lifted its position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 123.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,511,614 shares of the company's stock after acquiring an additional 835,000 shares during the period. Immunovant comprises approximately 3.2% of Two Seas Capital LP's holdings, making the stock its 10th largest holding. Two Seas Capital LP owned about 0.89% of Immunovant worth $37,443,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. KBC Group NV boosted its position in Immunovant by 60.1% during the 4th quarter. KBC Group NV now owns 3,099 shares of the company's stock valued at $77,000 after purchasing an additional 1,163 shares during the period. Rhumbline Advisers grew its position in shares of Immunovant by 1.5% during the fourth quarter. Rhumbline Advisers now owns 80,932 shares of the company's stock worth $2,005,000 after acquiring an additional 1,188 shares during the last quarter. Swiss National Bank increased its holdings in shares of Immunovant by 1.2% in the 4th quarter. Swiss National Bank now owns 100,800 shares of the company's stock worth $2,497,000 after acquiring an additional 1,200 shares during the period. Tyro Capital Management LLC lifted its position in Immunovant by 0.6% in the 3rd quarter. Tyro Capital Management LLC now owns 252,149 shares of the company's stock valued at $7,189,000 after purchasing an additional 1,529 shares during the last quarter. Finally, Sei Investments Co. boosted its stake in Immunovant by 4.0% during the 4th quarter. Sei Investments Co. now owns 40,456 shares of the company's stock valued at $1,002,000 after purchasing an additional 1,541 shares during the period. 47.08% of the stock is currently owned by institutional investors.

Immunovant Stock Up 5.5 %

Shares of IMVT traded up $0.84 during mid-day trading on Wednesday, reaching $16.06. The company's stock had a trading volume of 565,233 shares, compared to its average volume of 1,196,571. Immunovant, Inc. has a 1 year low of $12.72 and a 1 year high of $34.47. The company has a market cap of $2.73 billion, a price-to-earnings ratio of -6.13 and a beta of 0.81. The business has a fifty day moving average of $17.29 and a 200 day moving average of $22.87.

Immunovant (NASDAQ:IMVT - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.08). On average, analysts predict that Immunovant, Inc. will post -2.69 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have commented on IMVT. Wolfe Research lowered shares of Immunovant from an "outperform" rating to a "peer perform" rating in a research note on Friday, January 3rd. Guggenheim restated a "buy" rating on shares of Immunovant in a report on Thursday, March 20th. HC Wainwright reiterated a "buy" rating and issued a $51.00 price target on shares of Immunovant in a research report on Wednesday, March 19th. Jefferies Financial Group initiated coverage on shares of Immunovant in a research note on Monday, March 3rd. They issued a "hold" rating and a $20.00 price objective on the stock. Finally, Cantor Fitzgerald raised shares of Immunovant to a "strong-buy" rating in a research note on Tuesday, March 4th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $38.33.

Insider Buying and Selling

In other Immunovant news, CTO Jay S. Stout sold 1,925 shares of Immunovant stock in a transaction that occurred on Wednesday, April 23rd. The shares were sold at an average price of $14.79, for a total value of $28,470.75. Following the completion of the sale, the chief technology officer now directly owns 209,243 shares in the company, valued at $3,094,703.97. The trade was a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Andrew J. Fromkin sold 8,000 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $19.60, for a total transaction of $156,800.00. Following the transaction, the director now owns 91,913 shares in the company, valued at approximately $1,801,494.80. This trade represents a 8.01 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 51,682 shares of company stock worth $753,419. Corporate insiders own 5.90% of the company's stock.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.